Bradford A. Zakes

President & Chief Executive Officer

Mr. Zakes has served as Cerevast’s President and Chief Executive Officer since its inception in September 2009. Previously, he served as President and CEO of ImaRx Therapeutics, Inc. a publicly traded biopharmaceutical company focused on the development of microsphere technology and biotherapeutics. Mr. Zakes has spent 25+ years in various segments of the pharmaceutical, biotechnology and med-tech industries. Following his career as a commissioned officer in the United States Army, Mr. Zakes held positions at Hazleton Laboratories, Glaxo (currently Glaxo Smithkline) and ICOS Corporation. While at Glaxo, Mr. Zakes played an active role in the clinical development of Zantac™ and managed the sNDA clinical program that led to the approval of Serevent™ for chronic obstructive pulmonary disease. Mr. Zakes holds a BS degree in Biology from Oregon State University, an MS degree in Toxicology from the American University and an MBA from Duke University’s Fuqua School of Business. Additionally, Mr. Zakes serves on the Board of Directors for the Biotechnology Industry Organization (BIO) as well as the Emerging Company Section Governing Body and the Standing Committees on International Affairs and Budget and Audit for BIO.

Anthony J. Alleman

Chief Operating Officer

Mr. Alleman is a retired United States Navy officer with a distinguished career that included service on submarines, nuclear power engineering, and senior leadership positions on operational staffs. Since retiring from the Navy, Mr. Alleman has worked in private industry in operations and technical project management. At Advanced Inquiry Systems, a Portland, Oregon based startup semiconductor test equipment firm, he built a solely outsourced supply chain for the manufacture of an innovative wafer level test system. He successfully qualified and managed 10 key suppliers and managed the technical liaison to the internal engineering group during the product development phase. With extensive experience in operational excellence and Six Sigma, he has led projects to enhance plant and industry level productivity; encourage technology awareness and transfer for increased innovation; and led development efforts with a particular focus on emerging/startup firms. Mr. Alleman holds a BS in Mechanical Engineering from Oregon State University and an MBA from George Fox University

W.J. Tyler, Ph.D.

Chief Scientific Officer

Dr. Tyler is an Associate Professor in the School of Biological and Health Systems Engineering at Arizona State University. Dr. Tyler utilizes cutting-edge technology to investigate a wide range of problems in modern neuroscience with active research approaches spanning single ion channel biophysics to fMRI and EEG in behaving humans. He has made leading contributions to our understanding of synaptic transmission and brain plasticity underlying sensory encoding and cognitive processes, such as learning and memory. He has also led the scientific development and commercialization of non-invasive neuromodulation technologies. He was a co-founder and the Chief Scientific Officer of Thync, Inc. He has received several awards including a prestigious McKnight Endowment Fund for Neuroscience Technological Innovation Award and a Defense Advanced Projects Research Agency (DARPA) Young Faculty Award for his leadership and pioneering of neurotechnology. He is the author or co-author on 25+ peer-reviewed publications in leading scientific journals, as well as an inventor or co-inventor on more than 25 patents on methods and devices for non-invasive neuromodulation, brain stimulation, communications and cognitive enhancement. Dr. Tyler received his B.S. and Ph.D. from the University of Alabama at Birmingham and conducted his postdoctoral fellowship at Harvard University.

Mark Moehring, Ph.D.

Chief Technology Officer

Dr. Moehring is a recognized leader in the field of ultrasound with 30+ years of experience in medical ultrasound instrument design and signal processing. His research and product development focus has been in the field of Doppler ultrasound with primary emphasis in diagnostic and therapeutic cranial applications.   Dr. Moehring has been central to technology development in areas as diverse as transcranial blood flow monitoring, otitis media detection in children, embolus detection, and ultrasound enhanced thrombolysis.  Dr. Moehring is a senior member of the Institute of Electrical and Electronics Engineers (IEEE) and holds a Bachelor of Science in Physics from Harvey Mudd College and a Master of Science and Ph.D. in Electrical Engineering from the University of Washington.  Dr. Moehring is the inventor of 16 issued patents in ultrasound and hemodynamic monitoring technology.

Gordon Brandt, M.D

Chief Medical Officer

Dr. Gordon Brandt is Chief Medical Officer at Cerevast. His 25+ year focus has been on drug and device development, culminating in US and international regulatory approvals. From 2002 through 2008 he was employed by Nastech Pharmaceutical Company as Executive Vice President overseeing clinical and regulatory affairs. During that time Nastech received both NDA (new drug) and ANDA (generic drug) approvals. From 1997 to 2002 Dr. Brandt was Vice President of Clinical and Regulatory Affairs at Sonus Pharmaceuticals. Sonus received European approval via the Centralized Process for its ultrasound contrast agent, Echogen™. Earlier in his career, Dr. Brandt worked on imaging products including the first commercial magnetic resonance imaging system for Diasonics and a line of novel ultrasound systems for Siemens, resulting in approvals via the PMA, 510k, and CE mark routes. Dr. Brandt graduated phi beta kappa and Summa Cum Laude with an engineering degree from Yale and received his medical degree from the University of California San Francisco. Dr. Brandt holds five US patents.

Andrew Leo

Vice President of Quality

Mr. Leo is a quality management professional with 25+ years of experience in biomedical research and development organizations, including Brigham and Women’s Hospital. He recently served as the Senior Director of Quality and Laboratory Operations at Sonus Pharmaceuticals. He has established and maintained quality systems to support biomedical development programs, which have been validated through audits by major regulatory agencies and corporate partners. He has also led and completed several technology transfer projects to contract manufacturers, and has developed strong relationships with key suppliers and service providers. He is a senior member of the American Society for Quality.  Mr. Leo received holds a BS degree in Chemistry from the University of Washington and an MBA from the University of Phoenix.

Mike Rothmeyer

Senior Vice-President, Global Sales and Marketing

Mr. Rothmeyer is a business development professional with nearly 20 years of experience in the medical device industry.  He is credited with conceiving localized and disruptive go-to-market strategies leading to new market creation and long-term revenue growth in geographies worldwide.   While with Diagnostic Ultrasound Corp., Mr. Rothmeyer was a leader in the global market development of BladderScan ultrasound measurement devices and GlideScope video laryngoscopes, both of which established new clinical standards of care across the health care continuum.  As Vice-President of Global Sales and Executive Team member with Verathon, Inc., he was directly involved in evolution of the company from a privately held, high-growth start-up to a top performing subsidiary of Roper Technologies Inc. (S&P ROP).  Mr. Rothmeyer holds a bachelor’s degree from Western Washington University.